Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

150.33 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2026 Add to My Watchlist

Price and Volume

Volume	1,542
Open	150.33
Bid (Size)	135.00 (100)
Ask (Size)	240.52 (200)
Prev. Close	150.33
Today's Range	150.33 - 150.33
52wk Range	49.81 - 161.38
Shares Outstanding	98,935,025
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands ↗

August 16, 2026

Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN...

Via MarketBeat

Palvella (PVLA) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy.

Via The Motley Fool

Performance

YTD	+49.9%	+49.9%
1 Month	+5.2%	+5.2%
3 Month	+29.8%	+29.8%
6 Month	+1.3%	+1.3%
1 Year	+166.3%	+166.3%

More News

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 05, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗

May 07, 2026

Via Chartmill

Palvella Therapeutics Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call ↗

August 04, 2026

Via Benzinga

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 04, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

July 30, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

July 28, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors

June 30, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

June 29, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗

June 27, 2026

Via The Motley Fool

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

June 22, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

June 03, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 02, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

May 27, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

May 21, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular

May 20, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

May 15, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

May 13, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

May 04, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

April 30, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

April 20, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?

Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?

Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?

The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market

What is the current price of Palvella Therapeutics, Inc. - Common Stock?

The current price of Palvella Therapeutics, Inc. - Common Stock is 150.33

When was Palvella Therapeutics, Inc. - Common Stock last traded?

The last trade of Palvella Therapeutics, Inc. - Common Stock was at 08/27/26 04:00 PM ET

What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?

The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 14.87B

How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?

Palvella Therapeutics, Inc. - Common Stock has 15B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.